Anthropic's $400M acquisition of Coefficient Bio for domain-specific biotech data underscores substrate dimensions

The enrichment work will be done inside Anthropic post-close: Coefficient's two founders and the handful of ex-Genentech staff fold into Anthropic's healthcare life sciences unit under Eric Kauderer-Abrams, feeding Claude for Life Sciences. From Coefficient's seat the asset leaves outright in an all-stock deal reported at ~$400M.

The headline frames this as pricing substrate dimensions, but the public reporting is mixed: TechCrunch, BioSpace and InvestingNews describe fewer than 10 employees, no revenue and the deal functioning as an acqui-hire of computational-biology talent, and separate reporting notes Anthropic is standing up its own wet lab to generate proprietary data. What Anthropic appears to be paying for is the team's ability to produce and reason over drug-discovery data that feeds pharma buyers' decisions on which targets and molecules to pursue; whether a pre-existing proprietary dataset of material size c

At close, Coefficient as a standalone entity ceases: team, any models and whatever internal data it had cross fully to Anthropic, consistent with the author's prior ruling that treats this as an acquisition priced on the data asset. No carve-out, residual licence or ongoing Coefficient-side rake is reported.

Not determinable from public sources. The $400M headline for a sub-10-person, pre-revenue, eight-month-old company is widely remarked on, but there is no disclosed benchmark for the data or capability sold against which to judge whether the sellers under-priced.